Drug patents in the global landscape. ... The 2001 Doha Declaration clarified the scope of TRIPS, emphasizing that patent regulations should not prevent drug access during public health crises.

Patents on the drug Coreg, dating back to 1978, have long expired, enabling these price-saving generics. Yet this year, a federal jury deemed one generic carvedilol maker in violation of a patent ...

The implications of patent eligibility, inventorship, ownership, duty of disclosure, and freedom to operate in AI-augmented drug development present multifaceted inquiries that demand careful ...

Clinical-stage biopharma company Reunion Neuroscience Inc. REUN filed a lawsuit against drug ... patent, including the USPTO director to issue a corresponding certificate of correction; a ...

As the primary patent on Tuberculosis drug Bedaquiline expires in India and other countries on Tuesday, at least three Indian companies — Lupin, Natco and Macleods — are poised to bring out ...

LOUISVILLE, Ky., Nov. 18, 2024 /PRNewswire/ -- PharmassêtX Inc., a late-preclinical stage pharmaceutical development company, today announced that the US Patent and Trademark Office has ...

India Business News: MUMBAI: Price of patented drugs will be halved as soon as they lose patent protection or are on the verge of going off patent in India, providing much.

This is Part 4 of “Behind the Counter,” an in-depth video series demystifying the complex world of patents and drug pricing. Years ago, when a brand-name medication’s patent expired ...

Neurizon granted US patent for lead drug NUZ-001 to treat mTOR pathway-related diseases, ... (ODD) status from the US Food and Drug Administration (FDA) for NUZ-001 in May 2024.

India’s patent law amendments during ... from cost effective Indian generic drugs. Advt The civil society movement also led to a separate Declaration on TRIPS and Public Health during the ...

The patent follows receipt by Neurizon of Orphan Drug Designation (ODD) status from the US Food and Drug Administration (FDA) ...

In the first stage, the MHLW subjectively examines whether a generic product can be authorised based on patent information. In the second stage, the MHLW offers an opportunity for the innovator and ...